Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

Drug Profile

Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

Alternative Names: hENT1 cancer diagnostic - Ventana Medical Systems/Clovis Oncology; hENT1 Companion Diagnostic Test; hENT1 IHC assay

Latest Information Update: 11 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clovis Oncology; Ventana Medical Systems
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer

Most Recent Events

  • 11 Nov 2013 No development reported - Clinical-Phase-Unknown for Pancreatic cancer in USA (unspecified route)
  • 31 Dec 2010 Launched for Diagnostic tests in European Union (unspecified route)
  • 31 Dec 2010 Launched for Pancreatic cancer diagnosis in European Union (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top